Pfizer (PFE) Tops Q3 EPS by 44c, Beats on Revenue; Offers FY24 Guidance
Tweet
Share
E-mail
Get Alerts PFE Hot Sheet
Price: $27.80 -1.14%
EPS Growth %: -12.6%
Financial Fact:
Less: Net income attributable to noncontrolling interests: 0
Today's EPS Names:
TAYD, PKE, More
EPS Growth %: -12.6%
Financial Fact:
Less: Net income attributable to noncontrolling interests: 0
Today's EPS Names:
TAYD, PKE, More
Join SI Premium – FREE
Pfizer (NYSE: PFE) reported Q3 EPS of $1.06, $0.44 better than the analyst estimate of $0.62. Revenue for the quarter came in at $17.7 billion versus the consensus estimate of $14.92 billion.
GUIDANCE:
Pfizer sees FY2024 EPS of $2.75-$2.95, versus the consensus of $2.65. Pfizer sees FY2024 revenue of $61-64 billion, versus the consensus of $61.2 billion.
For earnings history and earnings-related data on Pfizer (PFE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- US government plans $4 billion loan to Vistra for nuclear upgrades - Bloomberg
- Yorkton Equity Group closes acquisition of property manager Yorkton Management
- Pfizer's Litfulo meets Phase 3 endpoints for vitiligo treatment
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
